Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 8/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 8/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948992 | 0.93 | UBE2M (0.48) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL6218807 | 0.90 | UBE2M (0.49) | UBE2MDCUN1D1ACHEOPRM1CHRM2 | |
| SCHEMBL948165 | 0.89 | UBE2M (0.45) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL949604 | 0.88 | UBE2M (0.48) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL949384 | 0.86 | UBE2M (0.47) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL6220319 | 0.83 | DCUN1D1 (0.51) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL947326 | 0.80 | OPRM1 (0.46) | UBE2MDCUN1D1ACHEOPRM1CHRM2 | |
| SCHEMBL6218746 | 0.79 | DCUN1D1 (0.48) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL6219028 | 0.78 | DCUN1D1 (0.52) | UBE2MDCUN1D1OPRM1CHRM2CHRM3 | |
| SCHEMBL948614 | 0.77 | ACHE (0.44) | UBE2MDCUN1D1ACHEOPRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | UBE2M 3668/4885DCUN1D1 3135/4885ACHE 4043/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | UBE2M 3895/4885DCUN1D1 3286/4885ACHE 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.